Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients.

Thumbnail Image

Files

Impact of Ultra High-risk Genetics on Real-world Outcomes of Transplant-eligible Multiple Myeloma Patients.pdf (828.13 KB)

Embargo End Date

ICR Authors

Pawlyn, Charlotte
 Kaiser, Martin

Authors

Panopoulou, A
Easdale, S
Ethell, M
Nicholson, E
Potter, M
Giotas, A
Woods, H
Thornton, T
Pawlyn, C
Boyd, KD
Kaiser, MF

Document Type

Journal Article

Date

2023-02-01

Date Accepted

2022-12-19

Abstract

Refined prediction of early relapse following standard-of-care (SoC) autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) could inform real-world risk-stratified post-ASCT strategies. We investigated the impact of double hit genetics (≥2 adverse markers: t(4;14), t(14;16), t(14;20), gain(1q), del(17p)) on outcome in 139 NDMM patients who underwent SoC ASCT between January 2014 and October 2019 at our center. Double hit genetics were associated with a significantly shortened progression-free survival (hazard ratio [HR] = 4.27, P < 0.001) and overall survival (HR = 4.01, P = 0.03), and characterized most early relapses. Our results support the real-world utility of extended genetic profiling for improved risk prediction in NDMM.

Citation

HemaSphere, 2023, 7 (2), pp. e831 -

DOI

10.1097/HS9.0000000000000831

URI

https://repository.icr.ac.uk/handle/internal/5692

Rights

http://creativecommons.org/licenses/by/4.0/

Source Title

HemaSphere

Publisher

WILEY

ISSN

2572-9241

eISSN

2572-9241
2572-9241

Collections

Genetics and Epidemiology

Research Team

Myeloma Molecular Therapy

Notes